Have a feature idea you'd love to see implemented?
Let us know!
VIRX Viracta Therapeutics Inc
Price (delayed)
$0.1519
Market cap
$6.04M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.1
Enterprise value
$9.82M
Viracta is a precision oncology company targeting virus-associated malignancies. The Company's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination
Highlights
The company's debt fell by 34% YoY and by 10% QoQ
VIRX's EPS is up by 11% YoY and by 5% from the previous quarter
The equity has plunged by 122% YoY
The quick ratio has dropped by 57% year-on-year and by 30% since the previous quarter
Key stats
What are the main financial stats of VIRX
Market
Valuations
Earnings
Shares outstanding
39.74M
Market cap
$6.04M
Enterprise value
$9.82M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$40.11M
EBITDA
-$39.67M
Free cash flow
-$34.8M
Per share
Balance sheet
Liquidity
EPS
-$1.1
Free cash flow per share
-$0.88
Book value per share
-$0.17
Revenue per share
$0
TBVPS
$0.55
Total assets
$21.96M
Total liabilities
$28.58M
Debt
$16.91M
Equity
-$6.62M
Working capital
-$6.77M
Debt to equity
-2.56
Current ratio
0.76
Quick ratio
0.74
Net debt/EBITDA
-0.1
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-114.4%
Return on equity
-680.3%
Return on invested capital
-296.5%
Return on capital employed
N/A
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VIRX stock price
How has the Viracta Therapeutics stock price performed over time
Intraday
0%
1 week
-3.8%
1 month
-36.71%
1 year
-72.09%
YTD
-73.35%
QTD
-34.36%
Financial performance
How have Viracta Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$47.21M
Net income
-$43.29M
Gross margin
N/A
Net margin
N/A
The net income has grown by 9% YoY and by 4.5% from the previous quarter
The operating income is up by 4.6% since the previous quarter and by 3.1% year-on-year
Growth
What is Viracta Therapeutics's growth rate over time
Valuation
What is Viracta Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
VIRX's EPS is up by 11% YoY and by 5% from the previous quarter
The equity has plunged by 122% YoY
Efficiency
How efficient is Viracta Therapeutics business performance
The ROE has plunged by 133% from the previous quarter
The return on assets has dropped by 95% year-on-year and by 24% since the previous quarter
The return on invested capital has dropped by 76% since the previous quarter
Dividends
What is VIRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VIRX.
Financial health
How did Viracta Therapeutics financials performed over time
The company's total assets is 23% lower than its total liabilities
The company's total assets has shrunk by 67% YoY and by 30% QoQ
The quick ratio has dropped by 57% year-on-year and by 30% since the previous quarter
Viracta Therapeutics's debt to equity has shrunk by 136% QoQ
The equity has plunged by 122% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.